Alfred Garfall
University of Pennsylvania Medical Center: Transplantation · Penn Medicine · University of Pennsylvannia
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alfred Garfall as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:26 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06056102 · CAR-T Cell Therapy for Desensitization in Kidney TransplantationNational Institute of Allergy and Infectious Diseases (NIAID) · recruiting · Kidney Transplant, Kidney Failure, End Stage Renal Failure on Dialysis · study chair
- Ph2NCT05932680 · Limited-duration TeclistamabAbramson Cancer Center at Penn Medicine · recruiting · Myeloma Multiple · principal investigator
- Ph2NCT05032820 · Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple MyelomaMedical College of Wisconsin · completed · Multiple Myeloma · principal investigator
- Ph1NCT03549442 · Up-front CART-BCMA With or Without huCART19 in High-risk Multiple MyelomaUniversity of Pennsylvania · active not recruiting · Multiple Myeloma · principal investigator
- Early Ph1NCT03173430 · Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple MyelomaAbramson Cancer Center at Penn Medicine · terminated · Multiple Myeloma · principal investigator
- Ph2NCT02794246 · CART-19 Post-ASCT for Multiple MyelomaUniversity of Pennsylvania · terminated · Multiple Myeloma · principal investigator
- Ph1/Ph2NCT02756728 · A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple MyelomaBioInvent International AB · terminated · Multiple Myeloma · principal investigator
- N/ANCT01958528 · Study Of Circulating Multiple Myeloma Cells As A Biomarker of MGUS And SMMAbramson Cancer Center at Penn Medicine · completed · a Diagnosis of MGUS or SMM by IMWG Criteria · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantationU01AI163087 · NIAID · UNIVERSITY OF PENNSYLVANIA · fiscal years 2021 to 2026 · $4,316,508 awarded in 2026Same name and institution; not confirmed by an ID
- Anti-Sox2 immunotherapy to prevent multiple myeloma relapseR21CA238108 · NCI · UNIVERSITY OF PENNSYLVANIA · fiscal years 2020 · $423,948 awarded in 2020Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Blood & Marrow Transplant Clinical Trials Network Data Coordinating CenterU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Mary Maresca Horowitz · fiscal years 2011 to 2016Named on NCT05032820
- A Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy ResearchU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · fiscal years 1998 to 2026Named on NCT05032820
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:26 UTC. The ranking covers the 200 most relevant of 15 PubMed records, and a shared surname and initials can bring in a namesake. All 15 on PubMed
- Teclistamab in Relapsed or Refractory Multiple Myeloma.N Engl J Med · 20221,126 citationsRCR 79.2
- B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.J Clin Invest · 2019660 citationsRCR 22.9
- Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.N Engl J Med · 2015476 citationsRCR 13.0
- 293 citationsRCR 14.8
- Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.JCI Insight · 2018144 citationsRCR 4.5
- 67 citationsRCR 7.4
- Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab.Clin Lymphoma Myeloma Leuk · 202448 citationsRCR 5.4
- The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma.Clin Cancer Res · 202142 citationsRCR 1.8
- Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation.Bone Marrow Transplant · 201533 citationsRCR 1.3
- 25 citationsRCR 1.4